Prospective Evaluation of Health-Related Quality of Life in Patients Undergoing Anterolateral Craniofacial Resection with Orbital Exenteration
Overview
Authors
Affiliations
This study was aimed to evaluate health-related quality of life in patients undergoing anterolateral craniofacial resection (AL-CFR) with orbital exenteration (OE) for malignant skull base tumors and to investigate the effects of early psychiatric intervention. Present study is a prospective, observational study. The study took place at the hospital department. Twenty-six consecutive patients were selected who underwent AL-CFR with OE at our hospital between 2005 and 2015. Health-related quality of life was assessed preoperatively and 3, 6, 12, and 24 months after surgery using the Hospital Anxiety and Depression Scale (HADS) and medical outcomes study 8-items Short Form health survey (SF-8). In all cases, psychiatric intervention was organized by the consultation liaison psychiatry team preoperatively and postoperatively. Ten (38.0%) of the 26 patients died and 16 (62.0%) were alive and disease-free at the end of the study. The 3-year overall and disease-free survival rates were 64.9% and 53.3%, respectively. Twenty-one patients (80.8%) developed psychiatric complications after surgery and needed treatment with psychotropic medication. Before surgery, 28% of patients had HADS scores ≥8 for anxiety and 20% had scores ≥8 for depression. Seven of the eight items in the SF-8 were significantly lower than those for the general Japanese population. However, scores for all the SF-8 items gradually improved during postoperative follow-up, reaching approximately 50 points, which is the national standard value, at 2 years after surgery. Craniofacial resection with OE was feasible and well tolerated in patients with malignant skull base tumors who received early psychiatric intervention to decrease the considerable psychological impact of this procedure.
Yokoi M, Nishio N, Kimura H, Tokura T, Kishi S, Tsuzuki H Laryngoscope Investig Otolaryngol. 2025; 10(2):e70109.
PMID: 40046985 PMC: 11877324. DOI: 10.1002/lio2.70109.
Determinants of quality of life following resection of skull base tumors: a systematic review.
Sperl V, Rhomberg T, Kretschmer T Front Oncol. 2025; 14:1473261.
PMID: 39759154 PMC: 11696366. DOI: 10.3389/fonc.2024.1473261.
Emerging Indications for Neoadjuvant Systemic Therapies in Cutaneous Malignancies.
Junior D, Cidale B, Pereira A, de Menezes J, Bertolli E, Belfort F Med Sci (Basel). 2024; 12(3).
PMID: 39189198 PMC: 11348210. DOI: 10.3390/medsci12030035.
Sato-Boku A, Tokura T, Kimura H, Ito M, Kishi S, Tonoike T Cureus. 2023; 15(9):e45586.
PMID: 37868420 PMC: 10587782. DOI: 10.7759/cureus.45586.
Qedair J, Haider A, Balasubramanian K, Palmisciano P, Hassan T, Shahbandi A Cancers (Basel). 2023; 15(17).
PMID: 37686561 PMC: 10487227. DOI: 10.3390/cancers15174285.